A Phase 3 Study to Evaluate the 1-Year Efficacy and Safety of Udenafil 75 mg Once Daily in Patients With Erectile Dysfunction

Once-daily administration of phosphodiesterase type 5 inhibitors has been shown to correct erectile dysfunction (ED).

To evaluate the long-term efficacy and safety after once-daily oral administration of udenafil 75 mg in men with ED.

This clinical trial was an open-label, fixed-dose, 24-week extension study (DA8159_EDDL_III) of a 24-week double-blinded efficacy and safety study of once-daily udenafil (parent study: DA8159_EDD_III). Subjects received udenafil 75 mg once daily for 24 weeks during this extension study, and the follow-up visit occurred during the 4-week ED treatment-free period.

Subjects were asked to complete the International Index of Erectile Function questionnaire and the Global Assessment Questionnaire at the 24-week extension and after the 4-week ED treatment-free period, and the development of adverse drug reactions was investigated.

In total, 302 subjects were enrolled in this extension study. Improvement was shown with an increased erectile function (EF) domain score compared with baseline (14.60 ± 4.57) at extension week 48 (23.98 ± 5.44) and a slight increase in EF domain score compared with the last time point (week 24) of the parent study (P < .001). The Global Assessment Questionnaire showed a high improvement rate of 95.4% at the extension 48-week time point. For shift to normal, almost half the subjects (45.1%) recovered "normal" EF, and 14.2% of subjects reported normal erections after the 4-week ED treatment-free period. The occurrence rate of adverse drug reactions was 8%, which consisted mainly of flushing and headache.

Once-daily dosing of udenafil 75 mg showed excellent efficacy and safety with long-term administration and allowed a more spontaneous sexual life.

The journal of sexual medicine. 2016 Jun 17 [Epub ahead of print]

Ki Hak Moon, Sae Woong Kim, Du Geon Moon, Je Jong Kim, Nam Cheol Park, Sung Won Lee, Jae-Seung Paick, Tai Young Ahn, Woo Sik Chung, Kwon Sik Min, Jong Kwan Park, Dae Yul Yang, Hong Seok Shin, Kwangsung Park

Department of Urology, College of Medicine, Yeungnam University, Daegu, Korea., Department of Urology, The Catholic University of Korea College of Medicine, Seoul, Korea., Department of Urology, College of Medicine, Korea University, Seoul, Korea., Department of Urology, College of Medicine, Korea University, Seoul, Korea., Department of Urology, Pusan National University School of Medicine, Busan, Korea., Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea., Department of Urology, Seoul National University Medical School, Seoul, Korea., Department of Urology, Asan Medical Center, Ulsan University School of Medicine, Seoul, Korea., Department of Urology, Ewha Womans University School of Medicine, Seoul, Korea., Department of Urology, College of Medicine, Inje University, Pusan, Korea., Department of Urology, Chonbuk National University Medical School, Jeonju, Korea., Department of Urology, College of Medicine, Hallym University, Seoul, Korea., Department of Urology, Catholic University of Daegu School of Medicine, Daegu, Korea., Department of Urology, Chonnam National University Medical School, Gwangju, Korea. Electronic address: .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe